CSIMarket Company Name, Ticker, Competitors, else..
 
Syros Pharmaceuticals Inc   (NASDAQ: SYRS)
 
Price: $0.0004 $0.00 0.000%
Day's High: $0.0010000000474974513 Week Perf: 300 %
Day's Low: $ 0.00 30 Day Perf: 300 %
Volume (M): 7,338 52 Wk High: $ 0.02
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 39
 Employees 47
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) -55
 Capital Exp. (TTM) (Millions $) 0

Business Description


Syros Pharmaceuticals Inc is a biopharmaceutical company focusing on developing gene control therapies for patients suffering from cancer and other diseases. They aim to target the underlying causes of these diseases by understanding the regulatory components of the genome and utilizing their proprietary gene control platform. Syros uses deep insights into genomic regulatory networks to identify and target specific genes that play a crucial role in controlling disease. Their goal is to pioneer a new wave of precision medicines that can effectively treat previously intractable diseases.


   Company Address: 35 CambridgePark Drive Cambridge 2140 MA
   Company Phone Number: 744-1340   Stock Exchange / Ticker: NASDAQ SYRS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALNY        12.24% 
BMRN        2.88% 
JAZZ        0.93% 
SUPN   -0.46%    
TGTX        3.81% 
VRTX        0.82% 
• View Complete Report
   



Business Update

Syros Pharmaceuticals, Inc. (NASDAQSYRS), based in Cambridge, Massachusetts, continues to pioneer advanceme...

Published Sun, Mar 2 2025 7:12 PM UTC

Syros Pharmaceuticals Announces Strategic Business Restructuring and Clinical Trial Developments Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), based in Cambridge, Massachusetts, continues to pioneer advancements in the field of hematologic malignancies. Today, the company has made significant announcements regarding its future trajectory and ongoing clinical research endeavors,...
Business Update

Syros Pharmaceuticals Faces Challenge with SELECT-MDS-1 Phase 3 Trial Results, Yet Remains Focused on Future Growth

Published Wed, Nov 13 2024 4:38 AM UTC

Syros Pharmaceuticals, a biopharmaceutical company specializing in the development of treatments for hematologic malignancies, recently announced topline data from their SELECT-MDS-1 Phase 3 trial. The trial investigated tamibarotene, combined with azacitidine, in treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. U...
Business Update

Syros Pharmaceuticals, a leading biopharmaceutical company specializing in the treatment of hematologic mal...

Published Wed, Jul 24 2024 1:47 PM UTC

Syros Pharmaceuticals Reports Second Quarter 2024 Financial Results: A Summary of Revenue Decline and Business UpdatesSyros Pharmaceuticals, a leading biopharmaceutical company specializing in the treatment of hematologic malignancies, has announced that it will be hosting a live conference call and webcast on July 31, 2024. The purpose of this event is to report the company...
Business Update

Syros Pharmaceuticals Reports Strong First Quarter 2024 Financial Results and Advances Tamibarotene for Frontline Treatment of Hematologic Malignancies

Published Tue, May 14 2024 12:47 PM UTC

Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to improving treatment options for hematologic malignancies, recently released its financial results for the first quarter of 2024. The company also shared an update on its progress in clinical and pre-commercial activities, specifically regarding the advancement of tamibarotene.During the first quarter of ...
Product Service News

Breakthrough or Bustn Syros Pharmaceuticals Nears Milestone in HR-MDS Treatment Trial

Published Mon, Mar 25 2024 11:00 AM UTC

In a significant development for the biopharmaceutical industry, Syros Pharmaceuticals has announced the successful completion of patient enrollment in the SELECT-MDS-1 Phase 3 clinical trial. The trial aims to evaluate the efficacy of tamibarotene in treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. With the enrol...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.04
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.05
Working Capital Ratio 2.25
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.12 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) -
Cash 1.48 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,081,170
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.